Thuro Bradley A, Ning Jing, Peng S Andrew, Pace Stanley T, Dudeja Gagan, Ozgur Omar, Turturro Franceso, Samaniego Felipe, Hagemeister Fredrick B, Fayad Luis E, Fowler Nathan H, Pinnix Chelsea C, Debnam J Matthew, Esmaeli Bita
*Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, †Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, ‡Department of Ophthalmology and Visual Sciences, The University of Texas Medical Branch, Galveston, Texas, U.S.A.; §Narayana Nethralaya, Narayana Health City, Bangalore, India; ‖Department of Lymphoma and Myeloma, ¶Department of Radiation Oncology, and #Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, U.S.A.
Ophthalmic Plast Reconstr Surg. 2017 Sep/Oct;33(5):355-360. doi: 10.1097/IOP.0000000000000789.
The aim of this study was to determine rates of positive findings on positron emission tomography (PET) and bone marrow biopsy performed during staging workup for ocular adnexal lymphoma (OAL).
A retrospective review of OAL patients was conducted. Demographics, primary versus secondary OAL, histologic subtype, and findings on PET and bone marrow biopsy performed as part of the initial staging workup for OAL were recorded.
The study included 119 patients with OAL. There were 85 primary and 34 secondary OALs. The main histologic subtypes of lymphoma were mucosa-associated lymphoid tissue (n = 61), follicular (n = 26), diffuse large B-cell (n = 17), and mantle cell (n = 10). Positive PET findings were seen in 42 of 68 patients (62%) with primary OAL and 19 of 24 (79%) with secondary OAL. Positive PET findings were seen in 24 of 47 patients (51%) with mucosa-associated lymphoid tissue, 13 of 17 (76%) with follicular, 14 of 15 (93%) with diffuse large B-cell, and 9 of 10 (90%) with mantle cell lymphoma. Positive findings on bone marrow biopsy were seen in 7 of 59 patients (12%) with mucosa-associated lymphoid tissue, 4 of 23 (17%) with follicular, 1 of 17 (6%) with diffuse large B-cell, and 2 of 9 (22%) with mantle cell lymphoma.
Our findings suggest that a significant proportion of patients with primary and secondary OAL have positive findings on PET and bone marrow biopsy at initial diagnosis, suggesting a reasonable yield for these tests as part of the initial staging workup in patients with a new diagnosis of OAL.
本研究旨在确定在眼附属器淋巴瘤(OAL)分期检查期间进行的正电子发射断层扫描(PET)和骨髓活检的阳性发现率。
对OAL患者进行回顾性研究。记录患者的人口统计学信息、原发性与继发性OAL、组织学亚型以及作为OAL初始分期检查一部分进行的PET和骨髓活检结果。
该研究纳入了119例OAL患者。其中原发性OAL 85例,继发性OAL 34例。淋巴瘤的主要组织学亚型为黏膜相关淋巴组织(n = 61)、滤泡性(n = 26)、弥漫性大B细胞(n = 17)和套细胞(n = 10)。68例原发性OAL患者中有42例(62%)PET检查结果为阳性,24例继发性OAL患者中有19例(79%)PET检查结果为阳性。黏膜相关淋巴组织淋巴瘤患者中,47例中有24例(51%)PET检查结果为阳性;滤泡性淋巴瘤患者中,17例中有13例(76%)PET检查结果为阳性;弥漫性大B细胞淋巴瘤患者中,15例中有14例(93%)PET检查结果为阳性;套细胞淋巴瘤患者中,10例中有9例(90%)PET检查结果为阳性。黏膜相关淋巴组织淋巴瘤患者中,59例中有7例(12%)骨髓活检结果为阳性;滤泡性淋巴瘤患者中,23例中有4例(17%)骨髓活检结果为阳性;弥漫性大B细胞淋巴瘤患者中,17例中有1例(6%)骨髓活检结果为阳性;套细胞淋巴瘤患者中,9例中有2例(22%)骨髓活检结果为阳性。
我们的研究结果表明,相当一部分原发性和继发性OAL患者在初诊时PET和骨髓活检有阳性发现,提示这些检查作为新诊断OAL患者初始分期检查的一部分,具有合理的阳性率。